

**Springer 3540545247**

# Prostaglandin E1: New Aspects on Pharmacology, Metabolism and Clinical Efficacy - Reference Guide

Edited by Curt Diehm, Helmut Sinzinger, and Waltraud Rogatti

## INTRODUCTION AND OVERVIEW

---

This book provides an in-depth exploration of Prostaglandin E1 (PGE1), a substance that has been clinically available for an extended period but whose effectiveness in peripheral arterial occlusive disease has only recently been confirmed through controlled studies. The favorable outcomes observed in patients with critical limb ischemia and intermittent claudication have significantly spurred research into its clinical pharmacology. The text highlights exciting new discoveries, including PGE1's anti-thrombotic, endothelium-stabilizing, and leukocyte-stabilizing properties, as well as its effects on lipid metabolism. These attributes, alongside its established anti-aggregating and vasodilator effects, contribute to its overall clinical efficacy. Furthermore, the book presents new data on PGE1 metabolism, particularly the identification of 13,14-dihydro-PGE1, a biologically active metabolite isolated in humans after PGE1 administration. The pharmacodynamic profile of 13,14-dihydro-PGE1 closely mirrors that of PGE1, offering insights into PGE1's efficacy despite its rapid metabolization when administered intravenously.

C. Diehm H. Sinzinger W. Rogatti (Eds.)

---

# Prostaglandin E<sub>1</sub>

---

New Aspects on Pharmacology, Metabolism  
and Clinical Efficacy



Springer-Verlag

The cover features the title 'Prostaglandin E<sub>1</sub>' prominently, along with the editors' names (C. Diehm, H. Sinzinger, W. Rogatti) and the subtitle 'New Aspects on Pharmacology, Metabolism and Clinical Efficacy'. The Springer-Verlag logo is visible at the bottom.

## KEY RESEARCH AREAS

---

The volume delves into several critical aspects of PGE1, including:

- Pharmacology of Prostaglandin E1
- Metabolism of PGE1, including the discovery of 13,14-dihydro-PGE1
- Clinical efficacy in peripheral arterial occlusive disease
- Anti-thrombotic properties
- Endothelium-stabilizing effects
- Leukocyte-stabilizing properties
- Impact on lipid metabolism
- Vasodilator and anti-aggregating effects

## INTENDED AUDIENCE AND USAGE

---

This book is an essential resource for researchers, clinicians, pharmacologists, and students in the fields of cardiovascular medicine, internal medicine, and pathology. It serves as a comprehensive reference for understanding the latest advancements in PGE1 research and its therapeutic applications. Readers can utilize this text for in-depth study, clinical reference, and staying current with pharmacological developments.

## BOOK SPECIFICATIONS

---

Attribute	Detail
Publisher	Springer
Publication Date	January 20, 1992
Edition	1st
Language	English
Print Length	128 pages
ISBN-10	3540545247
ISBN-13	978-3540545248
Item Weight	6.9 ounces
Dimensions	6.1 x 0.31 x 9.25 inches

## PUBLISHER INFORMATION AND SUPPORT

---

This publication is brought to you by Springer, a leading global scientific, technical, and medical portfolio, providing researchers in academia, scientific institutions and corporate R&D departments with quality content through innovative information products and services.

For inquiries regarding the content, errata, or academic use of this publication, please refer to the official Springer website or contact their customer support channels directly. Specific support details are typically available on the publisher's official platforms.

